Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X9HB
|
|||
| Former ID |
DIB001582
|
|||
| Drug Name |
MKT-077
|
|||
| Synonyms |
FJ-776 (formerly); SDZ-MKT-077; 1-Ethyl-2-[3-ethyl-5-(3-methyl-2,3-dihydrobenzothiazolin-2-ylidene)-4-oxothiazolidin-2-ylidenemethyl]pyridinium chloride
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [1], [2], [3] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H22ClN3OS2
|
|||
| Canonical SMILES |
CCN1C(=CC2=CC=CC=[N+]2CC)SC(=C3N(C4=CC=CC=C4S3)C)C1=O.[Cl-]
|
|||
| InChI |
1S/C21H22N3OS2.ClH/c1-4-23-13-9-8-10-15(23)14-18-24(5-2)20(25)19(27-18)21-22(3)16-11-6-7-12-17(16)26-21;/h6-14H,4-5H2,1-3H3;1H/q+1;/p-1/b21-19+;
|
|||
| InChIKey |
VSKYOTRJSLYFHX-UXJRWBAGSA-M
|
|||
| CAS Number |
CAS 147366-41-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mortalin (HSPA9) | Target Info | Modulator | [1], [2], [3] |
| KEGG Pathway | RNA degradation | |||
| Tuberculosis | ||||
| NetPath Pathway | TSH Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| Panther Pathway | Parkinson disease | |||
| Reactome | Mitochondrial protein import | |||
| Regulation of HSF1-mediated heat shock response | ||||
| WikiPathways | Mitochondrial Protein Import | |||
| Parkin-Ubiquitin Proteasomal System pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res. 2000 Dec 15;60(24):6818-21. | |||
| REF 2 | Mortalin sensitizes human cancer cells to MKT-077-induced senescence. Cancer Lett. 2007 Jul 18;252(2):259-69. | |||
| REF 3 | Analogs of the Allosteric Heat Shock Protein 70 (Hsp70) Inhibitor, MKT-077, as Anti-Cancer Agents. ACS Med Chem Lett. 2013 Nov 14;4(11). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.